Skip to content
E
ERPResearch

Infor M3 for Pharmaceuticals: FDA Compliance & Batch Manufacturing ERP

How Infor M3 supports pharmaceutical and biotech manufacturers with FDA 21 CFR Part 11 compliance, batch management, and quality control.

Infor M3 for Pharmaceutical & Biotech Manufacturing

Pharmaceutical manufacturing operates under some of the strictest regulatory requirements of any industry. ERP systems must support FDA 21 CFR Part 11 compliance, validated batch processing, full traceability, serialization, and rigorous quality management — while also handling the commercial and supply chain complexities of global drug distribution.

Infor M3, available as Infor CloudSuite, provides process manufacturing capabilities that align well with pharmaceutical and biotech requirements. This guide covers what M3 delivers for pharma, where it excels, and how it compares to alternatives.

Evaluating ERP for pharma or biotech? Get independent pricing and partner recommendations.

Get Infor Pricing Compare Infor M3


Pharmaceutical Industry ERP Challenges

Pharma manufacturers face unique ERP requirements that generic systems struggle to address:

ChallengeWhy It's Difficult
FDA 21 CFR Part 11Electronic records and electronic signatures must be validated, tamper-evident, and auditable
Batch traceabilityFull genealogy from raw API/excipient lots through production to distributed finished product
Validated environmentsERP system must operate within a validated state; changes require change control and revalidation
Quality managementGMP (Good Manufacturing Practice) requires integrated deviation management, CAPA, and stability testing
SerializationFDA DSCSA (Drug Supply Chain Security Act) and EU FMD require unique serial numbers on packaging
Potency managementActive pharmaceutical ingredient (API) potency varies by batch and affects formulation
Shelf life managementRegulatory and commercial shelf life constraints with country-specific requirements
Multi-country regulatoryDifferent approval statuses, labeling requirements, and market authorizations per country

Infor M3 Capabilities for Pharma

FDA 21 CFR Part 11 Compliance

21 CFR Part 11 governs electronic records and electronic signatures in FDA-regulated environments. Infor M3 provides:

  • Electronic signatures — Configurable e-signature capture for critical transactions (batch release, quality approvals, deviation closures)
  • Audit trails — Immutable audit logs recording who changed what, when, and why across all regulated transactions
  • Access controls — Role-based security with password policies, session management, and user authentication
  • Data integrity — System-enforced data validation rules preventing unauthorized modification of batch records

Important: FDA compliance is not a software feature alone — it requires validation. Implementing M3 in a pharma environment includes IQ/OQ/PQ (Installation, Operational, and Performance Qualification) as part of the validation lifecycle. This adds significant time and cost to implementation but is non-negotiable for FDA-regulated facilities.

Batch Process Management

M3's batch manufacturing capabilities support pharmaceutical production workflows:

  • Master batch records — Define production recipes with exact ingredient specifications, process parameters, and quality checkpoints
  • Batch execution — Real-time recording of actual production data against the master batch record
  • Yield tracking — Actual vs. theoretical yield tracking with automatic variance reporting
  • Potency-based formulation — Adjust ingredient quantities based on API potency test results for each incoming lot
  • Co-product and by-product management — Handle production outputs that generate multiple products from a single process
  • Batch genealogy — Full forward and backward traceability linking API lots, excipient lots, intermediate products, and finished goods

Quality Management (GMP)

M3's quality module supports pharmaceutical GMP requirements:

GMP RequirementM3 Capability
Incoming material testingQuality inspection at receipt with sampling plans and CoA verification
In-process controlsQuality checks linked to production steps with pass/fail disposition
Finished goods releaseMulti-level quality review and approval workflow before batch release
Deviation managementFormal deviation reporting with investigation, root cause analysis, and corrective actions
CAPACorrective and Preventive Action tracking with effectiveness verification
Stability testingSample management and stability study tracking for product shelf life determination
Supplier qualificationSupplier quality scoring, approved supplier lists, and vendor audit tracking
Document controlVersion-controlled SOPs and work instructions linked to production processes

Serialization & Track-and-Trace

The pharmaceutical industry faces increasing serialization mandates:

  • FDA DSCSA — Requires unique product identifiers on pharmaceutical packages by November 2024 (extended deadlines apply)
  • EU Falsified Medicines Directive (FMD) — Requires serialization and verification for prescription medicines
  • China, Brazil, others — Country-specific serialization requirements

M3 provides the product data management foundation for serialization and integrates with specialized serialization solutions (TraceLink, SAP ATTP, Antares Vision) via Infor ION middleware. The integration handles:

  • Serial number generation and assignment
  • Aggregation (serial to case to pallet)
  • Commissioning and decommissioning events
  • Regulatory reporting to national verification systems

Shelf Life & Expiry Management

  • Lot-level shelf life tracking with configurable date types (manufacturing date, expiry date, retest date)
  • FEFO (First Expired, First Out) warehouse management
  • Country-specific minimum remaining shelf life requirements
  • Automatic quarantine of expired or near-expiry lots
  • Stability-based shelf life extension workflows

Implementation Considerations for Pharma

Validation Requirements

Pharma implementations require a validated computing environment per GAMP 5 (Good Automated Manufacturing Practice) guidelines:

PhaseActivitiesTypical Duration
PlanningValidation strategy, risk assessment, validation master plan4–8 weeks
IQ (Installation Qualification)Verify software installed correctly per specifications2–4 weeks
OQ (Operational Qualification)Verify system functions per functional specifications6–12 weeks
PQ (Performance Qualification)Verify system performs correctly in production-like conditions4–8 weeks
OngoingChange control, periodic review, revalidation as neededContinuous

Validation adds 30–50% to the implementation timeline and 20–40% to the cost compared to a non-regulated implementation. This is unavoidable for FDA-regulated manufacturers.

Typical Costs for Pharma Manufacturers

Company SizeAnnual LicenseImplementation (incl. validation)First-Year Total
Small Pharma (50–100 users)$150K–$300K$300K–$800K$450K–$1.1M
Mid-Market Pharma (100–300 users)$300K–$700K$600K–$1.8M$900K–$2.5M
Large Pharma (300+ users)$700K–$1.5M$1.5M–$4M+$2.2M–$5.5M+

Integration Requirements

Pharma facilities typically require integration between M3 and:

  • LIMS (Laboratory Information Management System) — Quality test results and CoA data
  • MES (Manufacturing Execution System) — Shop floor data collection and batch record execution
  • Serialization platforms (TraceLink, SAP ATTP) — Serial number management and regulatory reporting
  • DMS (Document Management System) — SOPs, batch records, regulatory submissions
  • Regulatory systems — FDA submission tracking, market authorization management

Compare ERP vendors side by side

Use our interactive comparison tool to evaluate features, pricing, and fit across leading ERP systems.

Compare ERP Software

Infor M3 vs SAP for Pharmaceutical Manufacturing

DimensionInfor M3SAP S/4HANA
Batch processingExcellent (native process manufacturing)Excellent (PP-PI module)
21 CFR Part 11Supported (requires validation)Supported (requires validation)
Quality managementGood (integrated QM module)Excellent (QM module is more mature)
SerializationVia integration (TraceLink, etc.)Native (SAP ATTP) or via integration
Potency managementGood (native)Good (requires configuration)
Global regulatoryGoodExcellent (broader country coverage)
Partner ecosystemModerate (fewer pharma-specialist partners)Very large (many pharma-specialist SIs)
Implementation cost$$$$$$
Scalability$50M–$5B revenue$100M–$100B+ revenue
Time to implement12–24 months (with validation)18–36 months (with validation)

Key takeaway: SAP S/4HANA offers broader functionality and a larger pharma-specialist partner ecosystem, which is important for very large pharmaceutical companies with complex global operations. Infor M3 provides strong process manufacturing depth at a lower cost point, making it a compelling choice for small-to-mid-market pharma and biotech companies where cost efficiency matters.

For contract manufacturing organizations (CMOs/CDMOs), M3's multi-company architecture and batch process management capabilities are particularly well-suited.


Frequently Asked Questions

Is Infor M3 validated for FDA compliance?

Infor M3 is validatable — meaning the software provides the technical capabilities needed for 21 CFR Part 11 compliance (electronic signatures, audit trails, access controls). However, validation is the customer's responsibility. Each implementation must be validated through IQ/OQ/PQ per GAMP 5 guidelines, and that validation is specific to your configuration and processes.

Can Infor M3 handle pharmaceutical serialization?

M3 does not include a native serialization engine. It integrates with industry-leading serialization platforms (TraceLink, SAP ATTP, Antares Vision) via Infor ION to manage serial number assignment, aggregation, and regulatory reporting. This integration approach is common across ERP vendors — only SAP offers a fully native serialization module.

How does Infor M3 compare to dedicated pharma ERPs like BatchMaster?

BatchMaster offers deeper pharma-specific functionality (formulation, stability testing, regulatory submission management) for smaller organizations, but lacks M3's enterprise scalability and multi-country capabilities. M3 is the better choice for pharma companies with multi-site, multi-country operations or those planning significant growth. BatchMaster is better suited for single-site operations under $50M revenue.

What GAMP 5 software category is Infor M3?

Infor M3 is classified as a Category 4 (configured software) product under GAMP 5. This means it is a commercial-off-the-shelf system that requires configuration to meet specific business requirements. Validation effort focuses on verifying that the configured system meets user requirements (OQ/PQ), not validating the underlying software code.


Next Steps

Evaluating ERP for pharmaceutical manufacturing? Get independent pricing and connect with pharma-experienced implementation partners.

Get Infor Pricing Compare Infor M3

Related pages:

Compare the vendors mentioned in this article

See how Infor CloudSuite, Infor M3 stack up side by side.

Compare Mentioned Vendors

Vendors Mentioned in This Article

Related Resources

Have questions about this topic?

Our ERP experts can help you find the right solution for your business.

Join 2,000+ companies using ERP Research to find their ideal ERP